Charles Schwab Investment Management Inc. Sells 5,340 Shares of Bio-Techne Co. (NASDAQ:TECH)

Charles Schwab Investment Management Inc. lowered its position in Bio-Techne Co. (NASDAQ:TECHFree Report) by 0.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,411,824 shares of the biotechnology company’s stock after selling 5,340 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Bio-Techne were worth $96,103,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of TECH. Wetherby Asset Management Inc. raised its stake in Bio-Techne by 4.8% in the 1st quarter. Wetherby Asset Management Inc. now owns 737 shares of the biotechnology company’s stock worth $319,000 after purchasing an additional 34 shares in the last quarter. Evercore Wealth Management LLC increased its holdings in Bio-Techne by 9.3% in the 1st quarter. Evercore Wealth Management LLC now owns 575 shares of the biotechnology company’s stock valued at $249,000 after buying an additional 49 shares during the period. Toroso Investments LLC increased its holdings in Bio-Techne by 4.8% in the 3rd quarter. Toroso Investments LLC now owns 1,266 shares of the biotechnology company’s stock valued at $360,000 after buying an additional 58 shares during the period. Kentucky Retirement Systems Insurance Trust Fund increased its holdings in Bio-Techne by 4.9% in the 3rd quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 1,406 shares of the biotechnology company’s stock valued at $399,000 after buying an additional 66 shares during the period. Finally, Pearl River Capital LLC increased its holdings in Bio-Techne by 5.6% in the 1st quarter. Pearl River Capital LLC now owns 1,326 shares of the biotechnology company’s stock valued at $574,000 after buying an additional 70 shares during the period. Institutional investors and hedge funds own 94.64% of the company’s stock.

Bio-Techne Stock Down 0.0 %

NASDAQ:TECH opened at $67.95 on Monday. The firm’s 50 day simple moving average is $72.03 and its 200 day simple moving average is $70.78. The company has a debt-to-equity ratio of 0.23, a current ratio of 4.37 and a quick ratio of 3.03. Bio-Techne Co. has a one year low of $51.79 and a one year high of $89.91. The company has a market cap of $10.68 billion, a PE ratio of 49.24, a P/E/G ratio of 6.90 and a beta of 1.24.

Bio-Techne Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, February 26th. Investors of record on Monday, February 12th will be given a dividend of $0.08 per share. The ex-dividend date of this dividend is Friday, February 9th. This represents a $0.32 annualized dividend and a yield of 0.47%. Bio-Techne’s dividend payout ratio is presently 23.19%.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Scotiabank assumed coverage on shares of Bio-Techne in a report on Thursday. They issued a “sector outperform” rating and a $80.00 target price on the stock. KeyCorp decreased their price target on shares of Bio-Techne from $115.00 to $80.00 and set an “overweight” rating on the stock in a report on Wednesday, November 1st. Stifel Nicolaus lowered shares of Bio-Techne from a “buy” rating to a “hold” rating and set a $65.00 price target on the stock. in a report on Friday, February 2nd. Citigroup decreased their price target on shares of Bio-Techne from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Wednesday, November 1st. Finally, UBS Group assumed coverage on shares of Bio-Techne in a report on Thursday, December 7th. They set a “buy” rating and a $80.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $84.11.

View Our Latest Stock Analysis on Bio-Techne

Bio-Techne Company Profile

(Free Report)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.

Read More

Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne Co. (NASDAQ:TECHFree Report).

Institutional Ownership by Quarter for Bio-Techne (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.